Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BIIB059 in Systemic and Cutaneous Lupus Erythematosus
2015-004359-32Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (4 arms), sponsored by Biogen. Primary endpoint: Change from baseline in active joint count (28-joint assessment). Started Nov 2016; status: completed.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2015-004359-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004359-32.